J&J Immunotherapy Darzalex Ok’d for Expanded Combination Use – Zacks.com
|
J&J Immunotherapy Darzalex Ok’d for Expanded Combination Use
Zacks.com Johnson & Johnson (JNJ – Free Report) announced that its immunotherapy, Darzalex has been approved for use in combination with Celgene Corporation’s (CELG – Free Report) multiple myeloma drug Pomalyst (pomalidomide) and dexamethasone. |
|
CRISPR Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China
Nasdaq BASEL, Switzerland, June 19, 2017 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that China’s State Intellectual … Intellia Therapeutics (NTLA) Receives Patent for CRISPR/Cas …StreetInsider.com Intellia Therapeutics Announces Patent for CRISPR/Cas Genome …GuruFocus.com Intellia Therapeutics Inc (NTLA) Expected to Announce Earnings of -$0.41 Per ShareSports Perspectives High Point Observer –Equities.com all 17 news articles » |
|
CRISPR Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China
GlobeNewswire (press release) BASEL, Switzerland, June 19, 2017 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that China’s State Intellectual … |
|
Intellia Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China
GlobeNewswire (press release) CAMBRIDGE, Mass., June 19, 2017 (GLOBE NEWSWIRE) — Intellia Therapeutics (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR technology, today announced that China’s … Insider Selling: CRISPR THERAPTC (CRSP) CEO Sells 50000 Shares of StockStock Observer CRISPR Therapeutics AG (:CRSP) Shares Tick 1.44% For the WeekConcord Register Crispr Therapeutics AG (CRSP) Expected to Announce Earnings of -$0.49 Per ShareTranscript Daily Davidson Register all 8 news articles » |
Proactive Investors Australia |
Cynata Therapeutics achieves progress in stem cell technology
Proactive Investors Australia Cynata Therapeutics (ASX:CYP) has received the Notice of Allowance from the U.S. patent office for a patent application tied to its proprietary Cymerus™ stem cell technology. This patent application covers an important element of Cynata’s stem cell … |